CME Group (NASDAQ:CME) Given New $271.00 Price Target at JPMorgan Chase & Co.

CME Group (NASDAQ:CME) had its price objective raised by JPMorgan Chase & Co. from $266.00 to $271.00 in a research note published on Thursday,MarketScreener reports. JPMorgan Chase & Co. currently has an underweight rating on the financial services provider’s stock.

Several other equities analysts also recently commented on CME. Raymond James Financial increased their target price on shares of CME Group from $310.00 to $320.00 and gave the stock an “outperform” rating in a research report on Monday, April 6th. Barclays lowered their target price on shares of CME Group from $344.00 to $343.00 and set an “equal weight” rating on the stock in a research report on Monday. Royal Bank Of Canada increased their target price on shares of CME Group from $295.00 to $302.00 and gave the stock a “sector perform” rating in a research report on Thursday, February 5th. TD Cowen increased their target price on shares of CME Group from $328.00 to $340.00 and gave the stock a “buy” rating in a research report on Thursday, April 9th. Finally, Weiss Ratings raised shares of CME Group from a “buy (b+)” rating to a “buy (a-)” rating in a research report on Monday, March 2nd. Two investment analysts have rated the stock with a Strong Buy rating, eight have given a Buy rating, six have issued a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $309.94.

CME Group Price Performance

Shares of NASDAQ:CME opened at $296.22 on Thursday. The company has a current ratio of 1.03, a quick ratio of 1.03 and a debt-to-equity ratio of 0.12. CME Group has a 1 year low of $251.90 and a 1 year high of $329.16. The business has a fifty day simple moving average of $306.66 and a 200 day simple moving average of $285.27. The firm has a market cap of $106.23 billion, a price-to-earnings ratio of 26.54, a P/E/G ratio of 3.05 and a beta of 0.26.

CME Group (NASDAQ:CME) last announced its quarterly earnings data on Wednesday, February 4th. The financial services provider reported $2.77 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.75 by $0.02. The business had revenue of $1.65 billion during the quarter, compared to analyst estimates of $1.64 billion. CME Group had a return on equity of 14.65% and a net margin of 62.45%.CME Group’s quarterly revenue was up 8.1% compared to the same quarter last year. During the same period last year, the company earned $2.52 earnings per share. As a group, sell-side analysts predict that CME Group will post 10.49 earnings per share for the current fiscal year.

CME Group Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Thursday, March 26th. Stockholders of record on Tuesday, March 10th were given a $1.30 dividend. This is an increase from CME Group’s previous quarterly dividend of $1.25. This represents a $5.20 annualized dividend and a dividend yield of 1.8%. The ex-dividend date of this dividend was Tuesday, March 10th. CME Group’s dividend payout ratio (DPR) is 46.59%.

Insiders Place Their Bets

In other news, Director Dennis Suskind sold 748 shares of the firm’s stock in a transaction dated Friday, February 6th. The stock was sold at an average price of $300.00, for a total value of $224,400.00. Following the sale, the director directly owned 2,699 shares of the company’s stock, valued at approximately $809,700. This trade represents a 21.70% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Martin J. Gepsman sold 300 shares of the firm’s stock in a transaction dated Friday, February 20th. The shares were sold at an average price of $305.90, for a total value of $91,770.00. Following the completion of the sale, the director directly owned 24,999 shares in the company, valued at approximately $7,647,194.10. This represents a 1.19% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last ninety days, insiders sold 8,539 shares of company stock valued at $2,713,821. 0.30% of the stock is owned by company insiders.

Institutional Investors Weigh In On CME Group

Several hedge funds and other institutional investors have recently made changes to their positions in CME. Truist Financial Corp grew its position in CME Group by 8.9% during the third quarter. Truist Financial Corp now owns 70,712 shares of the financial services provider’s stock worth $19,106,000 after buying an additional 5,773 shares in the last quarter. Alley Investment Management Company LLC grew its position in CME Group by 86.0% during the third quarter. Alley Investment Management Company LLC now owns 29,223 shares of the financial services provider’s stock worth $7,896,000 after buying an additional 13,512 shares in the last quarter. Elevate Capital Advisors LLC grew its position in CME Group by 85.2% during the third quarter. Elevate Capital Advisors LLC now owns 8,519 shares of the financial services provider’s stock worth $2,302,000 after buying an additional 3,919 shares in the last quarter. SG Americas Securities LLC grew its position in CME Group by 345.2% during the fourth quarter. SG Americas Securities LLC now owns 237,898 shares of the financial services provider’s stock worth $64,965,000 after buying an additional 184,459 shares in the last quarter. Finally, Ashton Thomas Private Wealth LLC grew its position in CME Group by 78.8% during the third quarter. Ashton Thomas Private Wealth LLC now owns 13,281 shares of the financial services provider’s stock worth $3,588,000 after buying an additional 5,855 shares in the last quarter. 87.75% of the stock is owned by institutional investors and hedge funds.

Key CME Group News

Here are the key news stories impacting CME Group this week:

• Positive Sentiment: Regulatory approval for expanded U.S. Treasury cross‑margining with DTCC should lower client capital needs and deepen ties with fixed‑income clearing users, potentially boosting transaction volumes and stickiness. DTCC and CME cross‑margining approval
• Positive Sentiment: ESMA recognition of CME Group Benchmark Administration as a third‑country benchmark administrator validates Term SOFR usage in Europe and supports international distribution of CME’s rates products. ESMA recognition of CBA
• Positive Sentiment: CME is expanding its Equity Index Dividend suite (mid‑curve options and quarterly futures) and will add options on Eris SOFR swap futures — product launches that broaden revenue opportunities in equity and rates derivatives. Equity Index Dividend expansion Options on Eris SOFR swap futures
• Neutral Sentiment: Zacks and other outlets highlight expectations for earnings growth ahead of results — a potential catalyst if CME posts beats, but already priced partly into a relatively high P/E. Zacks earnings preview
• Neutral Sentiment: Institutional flows are mixed: large buys by some managers offset by big trims from others (e.g., UBS AM notably reduced exposure), leaving ownership rotation that can amplify intraday moves. QuiverQuant institutional holdings/flows
• Neutral Sentiment: Developments in decentralized finance/tokenized equities (Hyperliquid’s rapid growth in tokenized equity perps) are a watch item — potential long‑term competition for tradable equity derivatives but not an immediate revenue hit. Hyperliquid tokenized equity growth
• Negative Sentiment: CFTC is investigating suspicious oil futures trades on CME/ICE tied to geo‑political events — a regulatory probe that could create reputational risk, lead to compliance costs or tighter oversight. CFTC probe into oil futures trades MSN coverage
• Negative Sentiment: Significant insider selling (including CEO Terrence Duffy and other senior managers) and limited insider buys could signal management monetization and is likely weighing on sentiment. QuiverQuant insider trades & lobbying
• Negative Sentiment: Analyst views are mixed: Piper Sandler raised its target and kept an Overweight (positive signal), but JPMorgan maintains an Underweight and cut its downside target only slightly higher — plus recent notes from Rothschild & Co Redburn and Barclays lowered expectations, adding downward pressure. JPMorgan price target Piper Sandler target update Rothschild & Co Redburn note
• Neutral Sentiment: Lobbying disclosure (~$430k in Q1) shows CME is actively engaging regulators on clearing, digital assets and tax/treatment of futures — signals policy risk management but also highlights areas where outcomes could materially affect future revenue. Lobbying disclosure

About CME Group

CME Group Inc is a global markets company that operates some of the world’s largest and most liquid derivatives exchanges, including the Chicago Mercantile Exchange (CME), the Chicago Board of Trade (CBOT), the New York Mercantile Exchange (NYMEX) and COMEX. The firm offers futures and options contracts across a broad range of asset classes — including interest rates, equity indexes, foreign exchange, energy, agricultural commodities and metals — and serves a diverse client base of institutional investors, commercial hedgers, brokers and retail participants.

The company’s core services include electronic trading on the CME Globex platform, central clearing through CME Clearing, and distribution of market data, indexes and analytics.